Hong Xia, Li Yuan, Tao Chenjuan, Wang Gaofeng
Internal Department One, The Fourth People's Hospital of Lin'an District, Hangzhou, Zhejiang, China.
Department of Otolaryngology, Affiliated Hospital of Hangzhou Normal University (Hangzhou Second People's Hospital), Hangzhou, Zhejiang, China.
Front Integr Neurosci. 2025 Jul 21;19:1620845. doi: 10.3389/fnint.2025.1620845. eCollection 2025.
Central vertigo and peripheral vertigo are common clinical conditions with different underlying pathophysiologies. The identification of reliable biomarkers for differential diagnosis remains a challenge.
This study aimed to explore the differential expression of CCL4L2 in the serum of patients with central and peripheral vertigo and assess its diagnostic potential.
A total of 180 patients (90 central vertigo, 90 peripheral vertigo) were enrolled. RNA sequencing was on serum samples to identify differentially expressed genes (DEGs). Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis revealed relevant biological pathways. The expression of CCL4L2 was measured using RT-qPCR, and its diagnostic performance was evaluated by Receiver operating characteristic (ROC) curve analysis. The correlation between CCL4L2 expression and biomarkers NSE and S100β was also assessed.
RNA sequencing revealed significant differences in gene expression between central vertigo and peripheral vertigo groups. The KEGG pathway analysis identified several enriched pathways, including NF-κB signaling, where CCL4L2 was a key gene. CCL4L2 expression was significantly higher in the CV group compared to the PV group ( < 0.001). ROC analysis demonstrated high diagnostic accuracy for CCL4L2 in distinguishing CV from PV (AUC = 0.909, < 0.001). Additionally, moderate positive correlations were observed between CCL4L2 and NSE (r = 0.475, < 0.001), and a weaker correlation with S100β (r = 0.364, < 0.001).
CCL4L2 may serve as a potential biomarker for differentiating central from peripheral vertigo. Its expression is closely associated with inflammatory pathways, making it a promising target for further investigation in vertigo diagnostics.
中枢性眩晕和周围性眩晕是常见的临床病症，其潜在病理生理学不同。识别用于鉴别诊断的可靠生物标志物仍然是一项挑战。
本研究旨在探讨中枢性和周围性眩晕患者血清中CCL4L2的差异表达，并评估其诊断潜力。
共纳入180例患者（90例中枢性眩晕，90例周围性眩晕）。对血清样本进行RNA测序以鉴定差异表达基因（DEG）。京都基因与基因组百科全书（KEGG）通路富集分析揭示了相关生物通路。使用RT-qPCR检测CCL4L2的表达，并通过受试者操作特征（ROC）曲线分析评估其诊断性能。还评估了CCL4L2表达与生物标志物NSE和S100β之间的相关性。
RNA测序显示中枢性眩晕组和周围性眩晕组之间基因表达存在显著差异。KEGG通路分析确定了几个富集通路，包括NF-κB信号通路，其中CCL4L2是关键基因。与PV组相比，CV组中CCL4L2表达显著更高（<0.001）。ROC分析表明CCL4L2在区分CV与PV方面具有较高的诊断准确性（AUC = 0.909，<0.001）。此外，观察到CCL4L2与NSE之间存在中度正相关（r = 0.475，<0.001），与S100β的相关性较弱（r = 0.364，<0.001）。
CCL4L2可能作为区分中枢性和周围性眩晕的潜在生物标志物。其表达与炎症通路密切相关，使其成为眩晕诊断中进一步研究的有希望的靶点。
